As we approach the end of another successful year at Eclipsebio, I want to begin with gratitude.

To every member of our team who has given their energy, and dedicated their expertise, talent, and creativity into our mission - thank you. You are the reason Eclipsebio continues to blaze forward, helping our partners succeed in advancing RNA therapeutics.

Reflecting on our progress

In 2024, we launched eMERGE, our end-to-end sequencing-based platform for RNA therapeutics characterization. Industry adoption, by biotech innovators and major pharma partners alike has been amazing. It is a testament to the growing need for our advanced sequencing-based analytics that we are now supporting many of the 30 global biopharma advance their mRNA, saRNA and circRNA drug candidates to the clinic with key insights into RNA structure, translation, and purity.

While eMERGE anchors our offering, we have also expanded our portfolio in several key dimensions:

• Our miR-eCLIP+ assay addresses a major challenge in siRNA drug development: the direct measurement of off-target activity. This year, partners have rapidly adopted this technology to optimize and validate the next generation of RNAi therapeutics
• Our eVERSE database continues to gain traction as a foundation for AI model training in RNA therapeutics, helping close the data gap that has limited the effectiveness of AI in target discovery and drug design.
• We have expanded our sequencing capabilities to include nanopore sequencing, giving partners the ability to directly sequence RNA and gain insights into RNA quality that are not possible with other technologies.

These advances reflect our continued commitment not simply to provide analytical support, but to partner deeply with those developing the next generation of RNA medicines. Our brand promise remains the same: data-driven insights, not predictions; clarity, not black boxes.

The growing needs of RNA therapeutic development

RNA therapeutics continue to move beyond promise into clinical reality. With major regulatory milestones achieved, new modalities emerging, and manufacturing standards maturing, the field is shifting from “Can we do it?” to “Can we do it well?”

At Eclipsebio, we believe advanced, sequencing-based analytics are no longer optional: they are the foundation of high-quality RNA therapeutic development.

Over the past year, we have seen our partners focus on three key trends:

• Quality first: As the field expands from infectious disease vaccines to new classes of therapies such as mRNA-based gene editing, our partners are asking what RNA quality looks like when there is a critical need to minimize off-target effects and immune activation.
• Data scale: As cell-type-specific drug activity becomes increasingly important, multidimensional datasets are providing a competitive edge for those training effective AI models.
• Manufacturing analytics: The industry is reaching the limits of what traditional analytics can offer for guiding Quality by Design. There is growing demand for advanced sequencing-based analytics that illuminate the black box of RNA quality.

These are not incremental changes; they are redefining how RNA companies approach development, manufacturing, and commercialization.

Celebrating our culture and community

I am continually inspired by how our team shows up each day: solving complex problems, collaborating across disciplines, and staying relentlessly focused on partner success.

This year we were thrilled to support several early-stage drug companies and academic researchers through our Data Catalyst Award and RNA Innovators Award to provide rich RNA data for the design and characterization of tomorrow’s RNA medicines.

We also welcomed 5 new team members and celebrated key product launches, computational and AI advances, and revenue milestones including:

• Generating hundreds of thousands of data points from our advanced NGS assays to support our partners as the develop AI models for RNAi target discovery.
• The development of our own cutting-edge AI models for predicting the dynamics of translation, supporting the design of next-generation RNA therapies.
• Even deeper characterization of IVT RNA drugs with direct RNA sequencing.

To our partners, thank you for trusting us with your work. To our team, thank you for your passion, your insights, and your integrity. And to the next generation of scientists, engineers, and innovators, the opportunities to change the world with ground-breaking new RNA-based medicines have never been more immense. We all play a critical role and should embrace the challenges and journey together.  

Looking ahead

As I reflect on 2025, I feel a deep sense of optimism. The RNA field continues to unlock therapeutic pathways once considered out of reach. Eclipsebio is uniquely positioned to enable this progress through innovation, partnership, and a relentless focus on solving our partners’ greatest challenges.

Here’s to the breakthroughs yet to come and to the team that will make them possible. Together, let’s continue to turn RNA promise into patient impact.

Thank you for being part of this journey.